{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:29:37Z","timestamp":1793449777349,"version":"4.5.0"},"reference-count":36,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031220","name":"LabEx MAbImprove","doi-asserted-by":"crossref","award":["ANR-10-LABX-53-01"],"award-info":[{"award-number":["ANR-10-LABX-53-01"]}],"id":[{"id":"10.13039\/100031220","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2021,10,15]]},"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To identify patient characteristics associated with responsiveness to tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and methods<\/jats:title>\n                  <jats:p>Individual patient data from 29 randomised controlled trials (RCTs) evaluating the efficacy of a TNFi versus placebo or conventional therapy were obtained. Response to treatment was assessed in subgroups according to the following baseline characteristics: smoking status, physical activity, sex, age, body mass index, autoantibody profile, disease duration, high initial disease activity defined by Disease Activity Score on 28 joints (DAS28)(C reactive protein (CRP)) &gt;5.1. The primary outcome was the between-treatment group difference in DAS28(CRP) change from baseline to 6 months. The secondary endpoints were the between-treatment group difference in final DAS28(CRP) measured until 6 months and EULAR response criteria until 6 months. Data from each RCT were then pooled by the Mantel-Haenszel method using a random effects model. A linear metaregression was also carried out on two data-sharing platforms separately to support the results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Individual data of 11\u2009617 patients from 29 RCTs were analysed. Until 6 months, a significantly higher EULAR non-response rate was observed in obese patients (OR 0.52 vs 0.36 for non-obese, p=0.01). A multivariable regression model performed on 7457 patients indicated that patients treated by TNFi had a final DAS28(CRP) decreased by 0.02 for each year of disease duration (p&lt;0.001), and a 0.21 decreased for patients with a baseline DAS28(CRP) &gt;5.1 (p&lt;0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In RA, patients who are more responsive to TNFi are those who are non-obese, have a long disease duration and have a high initial disease activity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-001882","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T11:34:35Z","timestamp":1637148875000},"page":"e001882","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials"],"prefix":"10.1136","volume":"7","author":[{"given":"Johan","family":"Law-Wan","sequence":"first","affiliation":[{"name":"Department of Rheumatology, CHRU de Tours, Tours, France"},{"name":"EA 7501 GICC, Universit\u00e9 de Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Antoine","family":"Sparfel","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, CHRU de Tours, Tours, France"},{"name":"EA 7501 GICC, Universit\u00e9 de Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Derolez","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, CHRU de Tours, Tours, France"},{"name":"EA 7501 GICC, Universit\u00e9 de Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Azzopardi","sequence":"additional","affiliation":[{"name":"EA 7501 GICC, Universit\u00e9 de Tours, Tours, France"},{"name":"ERL 7001, CNRS, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Goupille","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, CHRU de Tours, Tours, France"},{"name":"EA 7501 GICC, Universit\u00e9 de Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Detert","sequence":"additional","affiliation":[{"name":"Medical Practice of Rheumatology and Clinical Immunology, Rheumatologisch-immunologische Praxis, Templin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4089-7513","authenticated-orcid":false,"given":"Denis","family":"Mulleman","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, CHRU de Tours, Tours, France"},{"name":"EA 7501 GICC, Universit\u00e9 de Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0018-9996","authenticated-orcid":false,"given":"Theodora","family":"Bejan-Angoulvant","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, CHRU de Tours, Tours, France"},{"name":"EA 4245 T2I, Universit\u00e9 de Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"2025090313550606000_7.3.e001882.1","doi-asserted-by":"publisher","DOI":"10.1186\/ar578"},{"key":"2025090313550606000_7.3.e001882.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1004965"},{"key":"2025090313550606000_7.3.e001882.3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)30173-8. PubMed PMID: 27156434."},{"key":"2025090313550606000_7.3.e001882.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"2025090313550606000_7.3.e001882.5","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200923020-00004"},{"key":"2025090313550606000_7.3.e001882.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.27227"},{"key":"2025090313550606000_7.3.e001882.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.20217"},{"key":"2025090313550606000_7.3.e001882.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901283400401"},{"key":"2025090313550606000_7.3.e001882.9","first-page":"5","article-title":"EpiDoC Unit - a clinical research unit open to the rheumatology community","volume":"46","author":"Canh\u00e3o","year":"2021","journal-title":"Acta Reumatol Port"},{"key":"2025090313550606000_7.3.e001882.10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel149"},{"key":"2025090313550606000_7.3.e001882.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.27758"},{"key":"2025090313550606000_7.3.e001882.12","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2012.677857"},{"key":"2025090313550606000_7.3.e001882.13","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9"},{"key":"2025090313550606000_7.3.e001882.14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110548"},{"key":"2025090313550606000_7.3.e001882.15","first-page":"1670","article-title":"Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study","volume":"34","author":"Mancarella","year":"2007","journal-title":"J Rheumatol"},{"key":"2025090313550606000_7.3.e001882.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094730"},{"key":"2025090313550606000_7.3.e001882.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.30136"},{"key":"2025090313550606000_7.3.e001882.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084715"},{"key":"2025090313550606000_7.3.e001882.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.01.005"},{"key":"2025090313550606000_7.3.e001882.20","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2348-6"},{"key":"2025090313550606000_7.3.e001882.21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken002"},{"key":"2025090313550606000_7.3.e001882.22","doi-asserted-by":"publisher","DOI":"10.1186\/ar1933"},{"key":"2025090313550606000_7.3.e001882.23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089442"},{"key":"2025090313550606000_7.3.e001882.24","article-title":"Non-pharmacological interventions for fatigue in rheumatoid arthritis","author":"Cramp","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090313550606000_7.3.e001882.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket216"},{"key":"2025090313550606000_7.3.e001882.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.11051"},{"key":"2025090313550606000_7.3.e001882.27","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00296-019-04284-x","article-title":"The impact of physical activity on serum levels of inflammatory markers in rheumatoid arthritis: a systematic literature review","volume":"39","author":"Burghardt","year":"2019","journal-title":"Rheumatol Int"},{"key":"2025090313550606000_7.3.e001882.28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3656"},{"key":"2025090313550606000_7.3.e001882.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390105"},{"key":"2025090313550606000_7.3.e001882.30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s13075-016-1194-8","article-title":"Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis","volume":"18","author":"Lupoli","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090313550606000_7.3.e001882.31","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0296-9"},{"key":"2025090313550606000_7.3.e001882.32","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12313"},{"key":"2025090313550606000_7.3.e001882.33","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2016.58928"},{"key":"2025090313550606000_7.3.e001882.34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001647"},{"key":"2025090313550606000_7.3.e001882.35","first-page":"343","article-title":"Strategies for dealing with missing data in clinical trials: from design to analysis","volume":"86","author":"Dziura","year":"2013","journal-title":"Yale J Biol Med"},{"key":"2025090313550606000_7.3.e001882.36","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.063834"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-001882","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:55:16Z","timestamp":1756932916000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-001882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,11,17]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/rmdopen-2021-001882"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-001882","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}